T from the 'independent report', a few quotes... http://www.hotcopper.com.au/asx_announcements.asp?id=25152
157,000 patients at a cost of US$72 per week (which we understand is consistent with the price of other HIV drugs) represents sales revenue of US$588 million for ATC
However, this ignores any opportunity for premium pricing given the advantages of ATC over current treatments. As evident from the introduction of Mercks new HIV agent Isentress,, HIV drugs typically achieve a higher price upon launch if they provide significant additional benefits to patients
Accordingly, Avexa considers that the valuation calculations contained in this report are inherently conservative.
3TC and FTC, as standalone or combination drugs are projected to generate sales of over US$3.2 billion in 2009
AVX Price at posting:
13.0¢ Sentiment: LT Buy Disclosure: Held
